Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing prospective multicenter single-arm observational study of diazoxide oral suspension for congenital hyperinsulinemic hypoglycemia
CTR20253912Phase 4Active
- Sponsor
- Suzhou Yifan Pharmaceutical
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of diazoxide in congenital hyperinsulinism (HI), sponsored by Suzhou Yifan Pharmaceutical. Started Feb 2026; status: active.
02
Drugs
diazoxide
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on CTR20253912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253912.